Effect of PP-01 on Cannabis Withdrawal Syndrome

Recruiting in Palo Alto (17 mi)

+18 other locations

Age: 18 - 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: PleoPharma, Inc.

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial is testing a medication called PP-01 to see if it can help people with severe cannabis use disorder feel better when they quit using cannabis. The study involves 225 participants and aims to reduce the uncomfortable withdrawal symptoms they experience.

Research Team

Jay Constantine, MD

Principal Investigator

PleoPharma, Inc.

Eligibility Criteria

Inclusion Criteria

Your body mass index (BMI) falls between 18.0 and 38.0 kg/m2.

Report heavy use of daily/near daily cannabis

Have a urine drug screen positive for tetrahydrocannabinol (THC)/THC metabolites at Screening and Randomization

See 6 more

Exclusion Criteria

You have been diagnosed with schizophrenia or schizoaffective disorder or bipolar 1 within the past 2 years.

You have a mental health condition that is currently unstable or may be affected by the study medication. If you have been taking medication for a stable condition for at least 3 months, the Investigator may decide to include you in the study.

You have a serious medical condition that is not under control.

See 6 more